New and emerging treatments for Alzheimer’s disease

References

• Wimo A, Prince M. World Alzheimer Report 2010. Alzheimer’s Disease International, London, UK (2010).
   Google Scholar
• Cappai R, Barnham KJ. Delineating the mechanism of Alzheimer’s disease A beta peptide neurotoxicity. Neurochem. Res.33(3), 526–532 (2008).
   PubMed Web of Science ®Google Scholar
• Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer’s disease. Int. J. Biochem. Cell Biol.41(6), 1261–1268 (2009).
   PubMed Web of Science ®Google Scholar
• Perry EK, Perry RH, Blessed G, Tomlinson BE. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet1(8004), 189 (1977).
   PubMed Web of Science ®Google Scholar
• Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst. Rev.1, CD001747 (2006).
   Google Scholar
• Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst. Rev.2, CD001191 (2009).
   PubMed Web of Science ®Google Scholar
• Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst. Rev.1, CD001190 (2006).
   PubMedGoogle Scholar
• Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer’s disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int. Psychogeriatr.21(5), 813–824 (2009).
   PubMed Web of Science ®Google Scholar
• Gauthier S, Feldman H, Hecker J et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Donepezil MSAD Study Investigators Group. Int. Psychogeriatr.14(4), 389–404 (2002).
   PubMed Web of Science ®Google Scholar
• Ballard C, Sorensen S, Sharp S. Pharmacological therapy for people with Alzheimer’s disease: the balance of clinical effectiveness, ethical issues and social and healthcare costs. J. Alzheimer’s Dis.12(1), 53–59 (2007).
   PubMed Web of Science ®Google Scholar
• Ballard CG, Chalmers KA, Todd C et al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology68(20), 1726–1729 (2007).
   PubMed Web of Science ®Google Scholar
• Chalmers KA, Wilcock GK, Vinters HV et al. Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer’s disease. J. Neurol.256(5), 717–720 (2009).
   PubMed Web of Science ®Google Scholar
• Lawlor BA, Davis KL. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer’s disease? Biological Psych.31(4), 337–350 (1992).
   Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA291(3), 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord.22(3), 209–221 (2008).
   PubMed Web of Science ®Google Scholar
• Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J. Clin. Psych.69(3), 341–348 (2008).
   Web of Science ®Google Scholar
• Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. Meta-analysis of six-month memantine trials in Alzheimer’s disease. Alzheimers Dement.3(1), 7–17 (2007).
   PubMed Web of Science ®Google Scholar
• Howard R, McShane R, Lindesay J et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N. Engl. J. Med.366, 893–903 (2012).
   PubMed Web of Science ®Google Scholar
• Hock C, Maddalena A, Raschig A et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer’s disease. Amyloid10, 1–6 (2003).
   PubMed Web of Science ®Google Scholar
• Bodick NC, Offen WW, Levey AI et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol.54(4), 465–473 (1997).
   PubMed Web of Science ®Google Scholar
• Sarazin M, de Souza LC, Lehéricy S, Dubois B. Clinical and Research diagnostic Criteria for Alzheimer’s Disease. Neuroimaging Clin. N. Am.22(1), 23–32 (2012).
   PubMed Web of Science ®Google Scholar
• Clare L, Linden DE, Woods RT et al. Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy. Am. J. Geriatric Psych.18(10), 928–939 (2010).
   PubMed Web of Science ®Google Scholar
• Yu F, Rose KM, Burgener SC et al. Cognitive training for early-stage Alzheimer’s disease and dementia. J. Gerontological Nursing35, 23–29 (2009).
   PubMed Web of Science ®Google Scholar
• Spector A, Thorgrimsen L, Woods B et al. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial. Br. J. Psych.183, 248–254 (2003).
   PubMed Web of Science ®Google Scholar
• Owen AM, Hampshire A, Grahn JA et al. Putting brain training to the test. Nature465(7299), 775–778 (2010).
   PubMed Web of Science ®Google Scholar
• Erickson KI, Voss MW, Prakash RS et al. Exercise training increases size of hippocampus and improves memory. Proc. Natl Acad. Sci. USA108(7), 3017–3022 (2011).
   PubMed Web of Science ®Google Scholar
• Baker LD, Frank LL, Foster-Schubert K et al. Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch. Neurol.67(1), 71–79 (2010).
   PubMed Web of Science ®Google Scholar
• Lautenschlager NT, Cox KL, Flicker L et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA300(9), 1027–1037 (2008).
   PubMed Web of Science ®Google Scholar
• Tomita T. Secretase inhibitors and modulators for Alzheimer’s disease treatment. Expert Rev. Neurother.9(5), 661–679 (2009).
   PubMed Web of Science ®Google Scholar
• Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics5(3), 481–489 (2008).
   PubMed Web of Science ®Google Scholar
• Gold M, Alderton C, Zvartau-Hind ME et al. Effects of rosiglitazone as monotherapy in apoE4-stratified subjects with mild-to-moderate Alzheimer’s disease. Alzheimers Dement.5(4), 86 (2009).
   Google Scholar
• Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer’s disease. Expert Opin. Pharmacother.10(10), 1657–1664 (2009).
   PubMed Web of Science ®Google Scholar
• Green RC, Schneider LS, Amato DA et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA302(23), 2557–2564 (2009).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Schneider LS, Cummings J et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch. General Psych.68(8), 853–861 (2011).
   PubMed Web of Science ®Google Scholar
• Mudher A, Shepherd D, Newman TA et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol. Psych.9(5), 522–530 (2004).
   PubMed Web of Science ®Google Scholar
• Leroy K, Ando K, Heraud C et al. Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J. Alzheimer’s Dis.19(2), 705–719 (2010).
   PubMed Web of Science ®Google Scholar
• Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. Feasibility and tolerability study of lithium in Alzheimer’s disease. Int. J. Geriatric Psych.23(7), 704–711 (2008).
   PubMed Web of Science ®Google Scholar
• Gura T. Hope in Alzheimer’s fight emerges from unexpected places. Nat. Med.14(9), 894 (2008).
   PubMed Web of Science ®Google Scholar
• Griffiths HH, Morten IJ, Hooper NM. Emerging and potential therapies for Alzheimer’s disease. Expert Opin. Ther. Targets12(6), 693–704 (2008).
   PubMed Web of Science ®Google Scholar
• Marcade M, Bourdin J, Loiseau N et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J. Neurochem.106(1), 392–404 (2008).
   PubMed Web of Science ®Google Scholar
• Desire L, Marcade M, Peillon H, Drouin D, Sol O. Clinical trials of EHT 0202, a neuroprotective and procognitive alpha-secretase stimulator for Alzheimer’s disease. Alzheimers Dement.5(4), 255 (2009).
   Google Scholar
• Jones RW. Dimebon disappointment. Alzheimers Res. Ther.2(5), 25 (2010).
   PubMed Web of Science ®Google Scholar
• McClean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J. Neurosci.31(17), 6587–6594 (2011).
   PubMed Web of Science ®Google Scholar
• Li Y, Duffy KB, Ottinger MA, Ray B et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J. Alzheimer’s Dis.19(4), 1205–1219 (2010).
   PubMed Web of Science ®Google Scholar
• Hemming ML, Selkoe DJ, Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol. Dis.26(1), 273–281 (2007).
   PubMed Web of Science ®Google Scholar
• Khachaturian AS, Zandi PP, Lyketsos CG et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch. Neurol.63(5), 686–692 (2006).
   PubMed Web of Science ®Google Scholar
• Li NC, Lee A, Whitmer RA et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ340, b5465 (2010).
   PubMed Web of Science ®Google Scholar
• Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol. Sci.25(12), 609–612 (2004).
   PubMed Web of Science ®Google Scholar
• Loeb MB, Molloy DW, Smieja M et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer’s disease. J. Am. Geriatrics Soc.52(3), 381–387 (2004).
   PubMed Web of Science ®Google Scholar
• Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol.6(8), 734–746 (2007).
   PubMed Web of Science ®Google Scholar
• Gilman S, Koller M, Black RS et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology64(9), 1553–1562 (2005).
   PubMed Web of Science ®Google Scholar
• Holmes C, Boche D, Wilkinson D et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled Phase I trial. Lancet372(9634), 216–223 (2008).
   PubMed Web of Science ®Google Scholar
• Schneeberger A, Mandler M, Otawa O, Zauner W, Mattner F, Schmidt W. Development of affitope vaccines for Alzheimer’s disease (AD) – from concept to clinical testing. J. Nutr Health Aging13(3), 264–267 (2009).
   PubMed Web of Science ®Google Scholar
• Winblad B, Minthon L, Floesser A et al. Results of the first-in-man study with the active Aβ immunotherapy CAD106 in Alzheimer patients. Alzheimers Dement.5(4), 113 (2009).
   Google Scholar
• Wilcock DM, Colton CA. Anti-amyloid-beta immunotherapy in Alzheimer’s disease: relevance of transgenic mouse studies to clinical trials. J. Alzheimers Dis.15(4), 555–569 (2008).
   PubMed Web of Science ®Google Scholar
• Relkin NR, Szabo P, Adamiak B et al. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging30(11), 1728–1736 (2009).
   PubMed Web of Science ®Google Scholar
• Siemers ER, Friedrich S, Dean RA et al. Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer’s disease. Alzheimers Dement.4(4), 774 (2008).
   Google Scholar
• Salloway S, Sperling R, Gilman S et al. A Phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology73(24), 2061–2070 (2009).
   PubMed Web of Science ®Google Scholar
• Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat. Rev. Mol. Cell Biol.8(2), 101–112 (2007).
   PubMed Web of Science ®Google Scholar
• Shankar GM, Li, S, Mehta TH et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med.14(8), 837–842 (2008).
   PubMed Web of Science ®Google Scholar
• Aisen PS, Saumier D, Briand R et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology67(10), 1757–1763 (2006).
   PubMed Web of Science ®Google Scholar
• Aisen P, Gauthier S, Ferris S et al. A Phase III, placebo-controlled, double-blind, randomized trial of tramiprosate in the clinical management of patients with mild-to-moderate Alzheimer’s disease (the Alphase study). Presented at: 61st American Academy of Neurology Annual Meeting. WA, USA, 25 April–2 May 2009 (Abstract S32.003).
   Google Scholar
• McLaurin J, Kierstead ME, Brown ME et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med.12(7), 801–808 (2006).
   PubMed Web of Science ®Google Scholar
• Garzone P, Koller M, Pastrak A et al. Oral amyloid anti-aggregating agent ELND005 is measurable in CSF and brain of healthy adult men. Alzheimers Dement.5(4), 323 (2009).
   Google Scholar
• Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot Phase 2 clinical trial. Arch. Neurol.60(12), 1685–1691 (2003).
   PubMed Web of Science ®Google Scholar
• Lannfelt L, Blennow K, Zetterberg H et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer’s disease: a Phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol.7(9), 779–786 (2008).
   PubMed Web of Science ®Google Scholar
• Wilcock DM, Colton CA. Anti-Aβ immunotherapy in Alzheimer’s disease; relevance of transgenic mouse studies to clinical trials J. Alzheimers Dis.15(4), 555–569 (2008).
   PubMed Web of Science ®Google Scholar
• Weinreb O, Amit T, Bar-Am O, Youdim MB. A novel anti-Alzheimer’s disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor. Int. Rev. Neurobiol.100, 191–215 (2011).
   PubMed Web of Science ®Google Scholar
• Maher-Edwards G, Zvartau-Hind M, Hunter AL et al. Double-blind, controlled Phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer’s disease. Curr. Alzheimer Res.7(5), 374–385 (2010).
   PubMed Web of Science ®Google Scholar
• Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J. Drug Targeting17(8), 564–574 (2009).
   PubMed Web of Science ®Google Scholar
• Blurton-Jones M, Kitazawa M, Martinez-Coria H et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl Acad. Sci. USA106(32), 13594–13599 (2009).
   PubMed Web of Science ®Google Scholar
• Yurko-Mauro K, McCarthy D, Rom D et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement.6(6), 456–464 (2010).
   PubMed Web of Science ®Google Scholar
• Kotani S, Sakaguchi E, Warashina S et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci. Res.56(2), 159–164 (2006).
   PubMed Web of Science ®Google Scholar
• Quinn JF, Raman R, Thomas RG et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA304(17), 1903–1911 (2010).
   PubMed Web of Science ®Google Scholar
• Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol.63(10), 1402–1408 (2006).
   PubMed Web of Science ®Google Scholar
• Freund-Levi Y, Basun H, Cederholm T et al. Omega-3 supplementation in mild to moderate Alzheimer’s disease: effects on neuropsychiatric symptoms. Int. J. Geriatr. Psychiatry23(2), 161–169 (2008).
   PubMed Web of Science ®Google Scholar
• Lloret A, Badía MC, Mora NJ et al. Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental. J. Alzheimers Dis.17(1), 143–149 (2009).
   PubMed Web of Science ®Google Scholar
• Remington R, Chan A, Paskavitz J et al. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer’s disease: a placebo-controlled pilot study. Am. J. Alzheimers Dis. Other Demen.24(1), 27–33 (2009).
   PubMed Web of Science ®Google Scholar
• Tong XK, Nicolakakis N, Fernandes P et al. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol. Dis.35(3), 406–414 (2009)
   PubMed Web of Science ®Google Scholar
• Feldman HH, Doody RS, Kivipelto M et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology74(12), 956–964 (2010).
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA289(21), 2819–2826 (2003).
   PubMed Web of Science ®Google Scholar
• Reines SA, Block GA, Morris JC et al. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology62(1), 66–71 (2004).
   PubMed Web of Science ®Google Scholar
• Rogers J, Kirby LC, Hempelman SR et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology43(8), 1609–1611 (1993).
   PubMed Web of Science ®Google Scholar
• Tabet N, Feldman H. Indomethacin for the treatment of Alzheimer’s disease patients. Cochrane Database Syst. Rev.2, CD003673 (2002).
   Google Scholar
• de Jong D, Jansen R, Hoefnagels W et al. No effect of one-year treatment with indomethacin on Alzheimer’s disease progression: a randomized controlled trial. PLoS ONE3(1), e1475 (2008).
   PubMed Web of Science ®Google Scholar
• Schmidt AM, Sahagan B, Nelson RB et al. The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer’s disease. Curr. Opin. Investig Drugs10(7), 672–680 (2009).
   PubMedGoogle Scholar
• Bates KA, Verdile G, Li QX et al. Clearance mechanisms of Alzheimer’s amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol. Psych.14(5), 469–486 (2009).
   PubMed Web of Science ®Google Scholar
• Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood–brain barrier. Stroke35(11 Suppl. 1), 2628–2631 (2004).
   PubMed Web of Science ®Google Scholar
• Shi JQ, Shen W, Chen J et al. Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res.1368, 239–247 (2011).
   PubMed Web of Science ®Google Scholar
• Rockwood K, Fay S, Song X, MacKnight C, Gorman M. Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomized controlled trial. Video-Imaging Synthesis of Treating Alzheimer’s Disease (VISTA) Investigators. CMAJ174(8), 1099–1105 (2006).
   PubMed Web of Science ®Google Scholar
• Rockwood K, Fay S, Gorman M, Carver D, Graham JE. The clinical meaningfulness of ADAS-Cog changes in Alzheimer’s disease patients treated with donepezil in an open-label trial. BMC Neurol.7, 26 (2007).
   PubMed Web of Science ®Google Scholar